Compugen Ltd. announced an amendment to its exclusive license agreement with AstraZeneca to monetize a portion of its future royalty interest in rilvegostomig. Under the updated terms, Compugen will receive an upfront payment of $65 million and may receive an additional $25 million upon reaching the next milestone related to BLA acceptance. The total potential value of the transaction is up to $90 million. Compugen will retain the majority of its future royalties and remains eligible for tiered royalties of up to mid-single digits on future sales, as well as potential future regulatory and commercial milestone payments of up to $195 million. The transaction is intended to extend Compugen's cash runway into 2029 and support its immuno-oncology pipeline development.